QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)

Resverlogix (RVX) Competitors

C$0.06
0.00 (0.00%)
(As of 03/4/2024 ET)

RVX vs. AEZS, HBP, APS, ATE, MBX, VPH, and WLLW

Should you be buying Resverlogix stock or one of its competitors? The main competitors of Resverlogix include Aeterna Zentaris (AEZS), Helix BioPharma (HBP), Aptose Biosciences (APS), Antibe Therapeutics (ATE), Microbix Biosystems (MBX), Valeo Pharma (VPH), and Willow Biosciences (WLLW). These companies are all part of the "medical" sector.

Resverlogix vs.

Resverlogix (TSE:RVX) and Aeterna Zentaris (TSE:AEZS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership.

Resverlogix has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Comparatively, Aeterna Zentaris has a beta of 2.02, indicating that its stock price is 102% more volatile than the S&P 500.

Resverlogix has higher earnings, but lower revenue than Aeterna Zentaris. Resverlogix is trading at a lower price-to-earnings ratio than Aeterna Zentaris, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ResverlogixN/AN/A-C$12.82M-C$0.05-1.10
Aeterna ZentarisC$6.86M1.82-C$23.37M-C$6.50-0.40

In the previous week, Aeterna Zentaris had 1 more articles in the media than Resverlogix. MarketBeat recorded 1 mentions for Aeterna Zentaris and 0 mentions for Resverlogix. Resverlogix's average media sentiment score of 0.00 equaled Aeterna Zentaris'average media sentiment score.

Company Overall Sentiment
Resverlogix Neutral
Aeterna Zentaris Neutral

0.7% of Aeterna Zentaris shares are held by institutional investors. 43.5% of Resverlogix shares are held by insiders. Comparatively, 0.2% of Aeterna Zentaris shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Resverlogix received 302 more outperform votes than Aeterna Zentaris when rated by MarketBeat users. However, 88.89% of users gave Aeterna Zentaris an outperform vote while only 84.01% of users gave Resverlogix an outperform vote.

CompanyUnderperformOutperform
ResverlogixOutperform Votes
310
84.01%
Underperform Votes
59
15.99%
Aeterna ZentarisOutperform Votes
8
88.89%
Underperform Votes
1
11.11%

Resverlogix's return on equity of 0.00% beat Aeterna Zentaris' return on equity.

Company Net Margins Return on Equity Return on Assets
ResverlogixN/A N/A -37.10%
Aeterna Zentaris N/A -61.74%-18.03%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Resverlogix
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Aeterna Zentaris
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Summary

Aeterna Zentaris beats Resverlogix on 7 of the 12 factors compared between the two stocks.


Get Resverlogix News Delivered to You Automatically

Sign up to receive the latest news and ratings for RVX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RVX vs. The Competition

MetricResverlogixBiotechnology IndustryMedical SectorTSE Exchange
Market CapC$14.97MC$306.45MC$4.88BC$4.20B
Dividend Yield7.02%3.41%5.38%7.01%
P/E Ratio-1.10208.10246.4520.78
Price / SalesN/A24,458.342,893.551,302.41
Price / Cash132.5013.6132.6071.00
Price / Book-0.215.044.463.36
Net Income-C$12.82M-C$15.28MC$111.94MC$281.51M
7 Day PerformanceN/A-0.10%4.12%1.93%
1 Month PerformanceN/A4.65%12.35%3.40%
1 Year PerformanceN/A76.38%13.08%3.32%

Resverlogix Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AEZS
Aeterna Zentaris
0 of 5 stars
C$2.50
-5.7%
N/A-42.3%C$12.15MC$6.86M-0.3911
HBP
Helix BioPharma
0 of 5 stars
C$0.18
+5.9%
N/A-11.9%C$39.00MN/A-6.009Gap Down
High Trading Volume
APS
Aptose Biosciences
0 of 5 stars
C$2.57
+1.6%
N/A+211.4%C$40.38MN/A-0.2531
ATE
Antibe Therapeutics
0 of 5 stars
C$0.99
-2.0%
N/A+86.5%C$52.14MC$9.71M-2.8311News Coverage
Gap Down
MBX
Microbix Biosystems
0 of 5 stars
C$0.40
-2.5%
N/A+17.6%C$53.94MC$22.42M13.17N/A
VPH
Valeo Pharma
0 of 5 stars
C$0.18
-5.4%
N/AN/AC$17.27MC$53.91M-0.55110Gap Down
WLLW
Willow Biosciences
0 of 5 stars
C$0.12
flat
N/A+9.5%C$14.91MC$1.59M-0.9232Gap Up

Related Companies and Tools

This page (TSE:RVX) was last updated on 3/4/2024 by MarketBeat.com Staff